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Abstract
There is an increasing number of experimental, genetic and clinical evidence of atopic dermatitis expression as a pre-condition for later development 
of other atopic diseases such as asthma, food allergy and allergic rhinitis.
Atopic dermatitis is a heterogeneous, recurrent childhood disease, also present in the adult age. It is increasingly attributed to systemic features and 
is characterized by immunological and skin barrier integrity and function dysregulation. To maintain the protective function of the skin barrier, in 
particular the maintenance of pH, hydration and antimicrobial functions, the filaggrin, among others, plays a significant role. Filaggrin is a multi-
functional, histidine-rich, insoluble protein. The lack of filaggrin is associated with various cutaneous (e.g. ichthyosis vulgaris, allergic contact derma-
titis) and non-cutaneous (e.g. diabetes, inflammatory conditions of the gastrointestinal tract) diseases and may be a result of genetic, immunologi-
cal factors combined with environmental factors.
In this review we summarised (emphasized) recent findings in understanding the role of filaggrin in atopic dermatitis and other diseases, partici-
pants in the atopic march.
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The term atopy, which was first coined by Coca 
and Cooke in 1923, represents immunoglobulin 
(Ig) E-mediated type I hypersensitivity reactions 
(1). Childhood atopic diseases typically develop in 
mucosal surfaces, such as skin, respiratory and 
gastrointestinal system, showing a high degree of 
comorbidity. Prevalence of atopic diseases, includ-
ing atopic dermatitis (AD), asthma, allergic rhinitis 
(AR), and food allergies (FA), has increased in re-
cent decades and currently affects up to 20% of 
the population worldwide (2). These diseases 
seem to be closely related. The process by which 
several atopic diseases are interconnected 
throughout life, in this case “progression” of AD 
into asthma and AR is an epidemiological phe-
nomenon commonly referred to as “atopic march” 
(3). The term refers to “time progression” from AD 
to asthma and AR during childhood, suggesting 
that AD is an “entry point” for subsequent atopic 
diseases (4-6) (Figure 1). However, there are opin-
ions that AD is not a causal factor for the atopic 
march, and that the sequence of events does not 
always have to be the same (7). Belgrave et al. in 
addition to some other researchers, question the 
paradigm of the atopic march, considering it’s too 
simplified and needs to be revised (8,9). They ex-
plain it by the fact that most of the studies involv-
ing atopic march have been conducted based on 
cross-sectional statistical analysis on the general 
population, not taking into account the heteroge-
Biochem Med (Zagreb) 2019;29(2):020501   https://doi.org/10.11613/BM.2019.020501 
2
Čepelak I. et al. Filaggrin and atopic march
neity of the chronology of the development of 
symptoms. They hypothesized that children with 
AD that later develop asthma and AR may repre-
sent a specific phenotype. Although mentioned in 
the context of the atopic march, evidence of AD 
related to FA is unclear and deficient (10). Accord-
ing to Hill et al. atopic diseases have some com-
mon multiple genetic and environmental predis-
posing factors, share immune characteristics of 
one or more allergen-specific Th2 responses, and 
include type 2 effectors phases in which specific 
IgE, granulocyte activation and other inherited 
factors occur (11). Most of the investigations of the 
causal nature of “progression” are aimed at seek-
ing evidence that supports the premise that AD of 
early childhood encourages the development of 
FA and respiratory allergies via systemic sensitiza-
tion resulting from impaired skin barrier function. 
Thus, the hypothesis that the main cause of atopic 
diseases is a defect in epithelial barrier integrity is 
accepted (12,13). The most investigated causes of 
the epidermal skin barrier impairment in AD, as 
the initiator of atopic march, are a lack of filaggrin 
(FLG) associated with decrease of ceramide and 
significant activation of epidermal proteases (14).
In this review, we focus on the FLG molecule and 
its importance in maintaining normal skin barrier 
function and on current knowledge of the signifi-
cance of FLG deficiency in diseases associated with 
atopic march. An overview of the recent knowl-
edge of the nature of these conditions and their 
association with the role of FLG will be given. Ap-
propriate scientific papers were selected on the 
PubMed using the following headings and key-
words, and their combinations: filaggrin, profilag-
grin, filaggrin mutations, atopic dermatitis, ecze-
ma, epidermal dysfunction, allergic rhinitis, food 
allergies and asthma. The search included epide-
miological, genetic and clinical examinations, 
mainly on patients of various ages, regardless of 
the ethnic group.
Atopic march development
Causes of skin barrier dysfunction can be intrinsic 
and extrinsic. Of the intrinsic causes, apart from 
the mutation of the gene encoding FLG, muta-
tions of numerous other genes, such as the SPINK5 
gene encoding a serum protein (Kazal type 5), and 
CDSN genes encoding corneodesmosin were in-
vestigated (15,16). Extrinsic causes are scratching, 
environmental irritation, microbes, viruses, protein 
allergens, etc. The reactions that follow skin barrier 
impairment and precede Th2 inflammation and 
IgE synthesis include various cytokines (e.g. inter-
leukine (IL)-25, IL-33 IL-4, IL-13, IL-5, etc.) and various 
































https://doi.org/10.11613/BM.2019.020501  Biochem Med (Zagreb) 2019;29(2):020501 
  3
Čepelak I. et al. Filaggrin and atopic march
cell types (e.g. basophilic and eosinophilic granu-
locytes, dendritic cells, mast cells and other types 
of cells). However, the TSLP (thymic stromal lym-
phopoietin), a type I cytokine produced by ke-
ratinocytes through the protease-activated recep-
tor-2 (PAR-2) mediated nuclear factor kappa B 
(PAR-2/NF-kB) pathway, has the greatest signifi-
cance. This cytokine has an essential role in the ini-
tiation of allergic inflammation in the skin. It acti-
vates Langerhans cells that promote differentia-
tion of naive T-cells in Th2 cells in lymph nodes 
(16,17). In addition, TSLP reduces the FLG expres-
sion in human skin, and acts as a sensory neuronal 
activator, resulting in itching (18,19). Some authors 
consider that TSLP in the circulation can be a mark-
er of lung responses to allergens. The TSLP could 
also be an important therapeutic target for reduc-
ing asthma and AR in children with AD (20).
Genetics play a greater role predisposing AD to AR 
and AD to asthma than environmental factors (21). 
In addition, the relationship between AD and asth-
ma, and between asthma and AR, does not de-
pend on common environmental factors of early 
life. Therefore, various genes were studied such as 
genes responsible for epidermal integrity (FLG, 
CLD, etc.), genes responsible for the functioning of 
the immune system (e.g. IL-13, IL-33, etc.), the non-
specific immune response participant genes (e.g. 
glutathione-S-transferase) and the genes respon-
sible for chronic tissue inflammation (e.g., COL29A1 
gene encoding collagen, ADAM33 gene expressed 
in fibroblasts and smooth muscle cells, etc.) (5,10). 
Despite differing opinions on the paradigm of at-
opic march, it is currently accepted that the prima-
ry disorder is the disturbed structure of the stra-
tum corneum (SC) or barrier function. Thereafter, 
an increased absorption of allergens (allergic sen-
sitization) predisposes the patients to the develop-
ment of other atopic diseases. Genetically or ac-
quired loss of FLG with epidermal structure impair-
ment results in significant changes in both skin hy-
dration and increased skin pH. Consequently, ser-
ine proteases activity is increased. Serine proteas-
es via suitable mediators recruit and activate in-
nate cell types that release IL-25, IL-33 cytokines, 
and particularly cytokine TSLP. The TSLP promotes 
the activation of dendritic cells, which migrate into 
the lymph organs and activate naive T cells and B 
cells, finally resulting in Th2 immune response. In-
creased penetration of allergens due to the dis-
turbed structure of the skin barrier contributes to 
the Th2 immune response. The TSLP and the pro-
inflammatory cytokines migrate to various path-
ways entering into systemic circulation and conse-
quently in the airway and nasal mucosa resulting 
in asthma and AR. On the other hand, Th2-cy-
tokines such as IL-4, IL-13, IL-25, as well as cytokines 
of other T-cell subtypes, whose number increases 
in AD depending on the subtype of disease, may 
suppress FLG expression in keratinocytes or aggra-
vate inborn barriers defect through positive loop 
feedback. The pattern of atopic march develop-
ment, including FLG deficiency and currently 
known major factors, is illustrated in Figure 2.
What is filaggrin? 
Filaggrin (from “FILament AGgregating pRoteIN) is 
a structural, S100 calcium-binding epidermal SC 
protein (22). It binds the intermediate filament of 
keratin producing micro-fibrils and is responsible 
for the normal SC function. It is a product of the 
proteolytic activity of the serine protease group 
enzymes to a large (molecular mass (Mm) > 400 
kDa), insoluble and functionally inactive precursor 
molecule - profilaggrin. Profilaggrin is a complex, 
highly phosphorylated molecule rich in histidine 
and is the main constituent of the F-type kerato-
hyaline granules of the stratum granulosum (SG). 
The profilaggrin expression is under the control of 
transcription factors such as the Activator protein 
1 (AP-1) transcription factor family members (23). 
Profilaggrin encodes the FLG gene, one of the 
genes that encode proteins with epidermis forma-
tion function. It is localized on the short arm of 
chromosome 1 and belongs to the group of so-
called epidermal differentiation complex (EDC), lo-
cated in region 1q21. During the epidermal differ-
entiation process of keratinocytes in the boundary 
between SG and SC, the profilaggrin molecule is 
dephosphorylated under the influence of phos-
phatase and becomes more soluble (24). Further 
action of different proteases results in cleavage of 
the profilaggrin molecule in several stages, sepa-
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rating the N- and C-terminal domains of the mole-
cule, splitting the central part into trimers and di-
mers, and finally into 10-12 functional monomers - 
the FLG molecules. Each FLG molecule consists of 
324 amino acids, with an Mm of 37 kDa. The result-
ing FLG monomers aggregate keratinic filaments 
along with the catalytic activity of the transglu-
taminase-1 enzyme, resulting in the marked mor-
phological and cytostructural changes of keratino-
cytes (become flattened corneocytes). In addition 
to FLG, many other proteins, such as loricrin, invo-
lucrin, small proline-rich proteins, are involved in 
the construction of the cornified envelope (25). In 
the further course of epidermal differentiation, 
separation of the part of FLG from the structure of 
the cornified envelope occurs resulting in post-
translational conversion of arginine residues into 
the citrulline residues. The transformed FLG mole-
cule is subject to the action of caspase-14 and is 
degraded. The FLG degradation products include 
a mixture of hygroscopic amino acids such as glu-
tamine, histidine, alanine and their derivatives 
such as trans-urocanic acid (tUCA), degradable 
product of histidine and pyrrolidone carboxylic 
acid (PCA), degradable glutamine and glutamic 
acid product (26). These compounds along with 
some other such as hyaluronic acid, lactate, sodi-
um, potassium, magnesium, phosphate, calcium, 
and citrate are the main constituents of so-called 
natural moisturizing factor (NMF) of the skin (27). 
The main characteristics of profilaggrin, FLG and 
its degradation products are presented in Table 1.
Figure 2. The mechanisms of atopic march. Inherited or acquired filaggrin deficiency results in immune and inflammatory changes. 
In addition, inflammatory and immune changes may result in filaggrin deficiency. Therefore, there is a positive feedback loop. Skin 
barrier impairment caused by deficiency of filaggrin; reduced filaggrin function leads to increased activity of TSLP, which through 
dendritic cells acts to promote both Th2 cell adaptive immune responses and Th2 innate immune cell response (marked as 1). Al-
lergen uptake and presentation to dendritic cells in a Th2 context (marked as 2). Th2 cell expansion and activation (marked as 3). B 
cells activation and IgE switch (marked as 4). Neutrophil recruitment and activation (marked as 5). Eosinophil recruitment and media-
tors’ release (marked as 6). Immunoglobulin E binding to the high-affinity IgE receptor (FcεRI), on mast cell and basophil receptors 
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To date, approximately 60 loss-of-function FLG 
mutations have been identified, with a difference 
in the spectra of mutations between different 
populations (28). The frequency of FLG mutation 
in the general population is 8-10%. The most com-
mon mutations in the European population are 
the R501X and 2282del4 mutations, resulting in 
premature transcription or inability to appropri-
ately process profilaggrin in FLG. Mutations R244x 
and S3247X were found with significantly lower 
frequency (29). Lack of functional FLG due to the 
FLG gene mutation and to inflammatory and pro-
inflammatory mediators that may affect FLG ex-
pression (acquired deficiency), results in a dysfunc-
tion of processes necessary for the corresponding 
protective SC role. 
Filaggrin and skin barrier
The skin barrier function is largely dependent on 
SC. The interior of the corneocytes consists mainly 
of keratin filaments aggregated by FLG, which is 
one of components that provide a scaffold for the 
extracellular lipid matrix. Filaggrin degradation 
products maintain in part for the both, water-hold-
ing capacity and acidic pH of the SC (25). Natural 
moisturizing factor components are essential for 
skin barrier integrity, i.e. for skin hydration, skin pH 
modulation, immunosuppressive properties, anti-
microbial defence, photosensitivity and skin elastic-
ity (27). Because of water loss, there is the loss of 
skin elasticity. Inadequate humidity of the skin can 
also stimulate the production of proinflammatory 
mediators. The skin pH, normally ranging from 4.5 
to 5.5, is increased. Endogenous causes of skin pH 
increase are amino acid deficiency, disruption of de-
composition of amino acids into tUCA and PCA, 
degradation of fatty acid from epidermal phospho-
lipids, and changes of Na+/H+ transmembrane 
transport. Increased pH results in increased activity 
of serine proteases that can activate some cytokines 
and cause inflammatory reactions. The exogenous 
causes of pH increase include the microbial skin flo-
ra metabolites, the activity of sweat glands, and se-
bum derived compounds. Changing pH from neu-
tral to alkaline values favours the development of 
various pathogens on the skin surface, most com-
monly Staphylococcus aureus and Candida albicans. 
All these changes result in reduced SC cohesion, 
enabling penetration of allergens and other patho-
gens in the skin. 
Filaggrin mutations, i.e. FLG deficiency is also asso-
ciated with various skin diseases (ichthyosis vulgar-
is, eczema herpeticum, atopic dermatitis, periodic 
infection with Staphylococcus aureus, allergy to 
nickel, allergic contact dermatitis in combination 
with AD, eczema, etc.) but also non-skin diseases 
(e.g. asthma in combination with AD, peanut aller-
gies, allergic rhinitis, diabetes) (30). 
Therapeutic approaches 
New therapeutic approaches directed to epider-
mal barrier defects are being attempted (31). Pri-
mary intervention in the treatment of diseases in-
volving FLG deficiency is directed to improving 
profilaggrin processing into FLG, the recombinant 
FLG supplementation, as well as the NMF supple-
mentation. It is believed that such a therapeutic 
approach could have a significant effect on a 
broader range of diseases associated with FLG 
gene mutation carriers, persons with FLG deficien-
Profilaggrin
(Mm > 400 kDa)
Filaggrin
(Mm ≈ 37 kDa)
Amino acids
(NMF)
Main constituent of keratohyalin granules, 
calcium-binding polyprotein, enucleation 
during cornification, keratinocyte-calcium 
signalling
Contribution to SC structure and function, 
aggregation of intermediate filaments, 
inhibition of transepidermal water loss
Epidermal hydration, acidification, 
photo protection, immunomodulation, 
antistaphyloccoccal effect
SC - stratum corneum. NMF - natural moisturizing factor. Mm – molecular mass. According to reference (27).
Table 1. Main characteristics of profilaggrin, filaggrin, and its degradation products (amino acids) 
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cy caused by inflammation, or in persons with ge-
netic or inflammatory enzyme variants that allow 
the conversion of profilaggrin into FLG. Most of 
the studies of the effects of such a therapy have 
been made in both animal models, and in vitro 
tests; the results are promising. However, a benefi-
cial effect on the development and progression of 
atopic march in human samples has yet to be es-
tablished. For more reliable conclusions about the 
effectiveness of such therapy, longer periods of 
disease monitoring are required. 
Atopic dermatitis and filaggrin
Atopic dermatitis is a common multifactorial skin 
disease of childhood, and it is postulated as the 
first manifestation of the atopic march (32). The 
prevalence of AD has increased in recent decades 
and currently affects up to 20-30% of children and 
to 3% of adults worldwide (3). It has some com-
mon features with FA, asthma and AR including 
abnormality of skin barrier function, allergen sen-
sitization and type 2 immune response (33). Clini-
cal manifestations of AD are the result of synergis-
tic action of genetic and immune mechanisms in 
combination with environmental factors (climate, 
nutrition, obesity, etc.). The disease is character-
ized by inflammation, immune dysregulation, skin 
barrier dysfunction, and in most but not all (10-
40% of AD patients) with IgE-mediated sensitiza-
tion to food and environmental allergens. Major 
symptoms include xerosis, eczema lesions, dry 
itchy skin, and chronic or relapsing dermatitis. 
Consequently, the continuous itchy-scratch cycle 
results in trans-epidermal water loss and second-
ary skin infections (34) (Figure 3). 
The form of AD with a normal serum IgE concen-
tration is known as a non-atopic or intrinsic AD. It 
is not related to other atopic diseases, but the clin-
ical picture does not differ from atopic or extrinsic 
AD (36). In addition to skin, systemic sensitization 
is also associated with AD. According to Brunner et 
al. various comorbidities are investigated, such as 
association with cardiovascular, neuropsychiatric, 
malignant diseases, but proof of this connection 
requires further longitudinal studies (37). Tradi-
tionally, the dysfunction of the adaptive immune 
system is considered a primary pathogenic mech-
Figure 3. The relationship between itching, skin barrier abnormalities and immune dysregulation. Scratching due to itching may ag-
gravate skin damage. Dry skin stimulates itching by increasing the density of epidermal nerve fibres. Scratching also promotes Th2 
chemokines, eosinophil recruiting chemokines, and TSLP. Obviously, the immune response can induce itching through the secretion 
of numerous cytokines that can act as a pruritogens. FLG – filaggrin. TSLP – thymic stromal lymphopoietin. Th – T helper. IL – inter-
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anism that initiates AD. Specifically including Th2/
Th1 imbalance and inflammation, which second-
ary results in skin-structure barrier impairment, 
which is considered an epiphenomenon. In a num-
ber of studies that followed the discovery of FLG 
gene mutation, an epidermal barrier impairment 
including FLG deficiency was considered as a pri-
mary pathogenic initiation mechanism of AD (38). 
According to Thyssen et al. the important observa-
tions that put FLG into the centre of pathogenesis 
of AD are: impaired FLG values in skin with or with-
out lesions in patients with AD, the fact that ap-
proximately 50% of patients with moderate or se-
vere AD have at least one FLG mutation, that a de-
crease in the number of copies of FLG increases 
the risk of AD, that the decreased values of FLG 
were demonstrated in skin lesions despite the ab-
sence of FLG mutations, and that some of the ex-
isting therapies can repair FLG values (39). The de-
velopment of AD, along with genetic and immune 
mechanisms, is also strongly influenced by envi-
ronmental factors such as industrialization, stress 
exposure, obesity, excessive use of antibiotics, 
sedentary lifestyle, etc (40). 
Specifically, the damaged skin-barrier function al-
lows penetration of various allergens/haptens, en-
vironmental pollutants, and toxins resulting from 
bacterial colonization on the one hand, and on the 
other hand by sensitization to allergens. For exam-
ple, it has been shown that phthalate metabolites, 
common ingredients of cosmetic products, in-
crease the risk of AD, and that children with FLG 
P478S mutations absorb phthalates (41). The 
pathogenesis of AD is also linked to FLG-2 gene 
mutations that encode the filaggrin-2, a protein 
similar to FLG by localization, amino-acid composi-
tion and biochemical properties (42). Also, other 
genes may play a role in the pathogenesis of AD, 
e.g. HRNR gene encoding the hornerin, RPTN gene 
encoding the repetin, a SPINK5 gene encoding Ka-
zal-type 5 serine protease, LOR gene encoding lo-
ricrin, and other genes by location close to epider-
mal differentiation complex (43-45). In addition, 
gene mutations that are involved in the immune 
response (e.g. IL-4, IL-5, IL-13, IL-18, IL-31, IL-4RA, a 
binding protein gene e.g. claudin (CLDN1) and des-
moglein 1 protein (DSG1) have been investigated 
(46,47). In the focus of the investigation of patho-
genesis of AD and atopic march is also a study of 
various epigenetic modifications such as methyla-
tion of DNA, FLG, TSLP, and variants of enzymes in-
volved in synthesis and profilaggrin processing 
(48). Most studies have shown that the lack of 
structural and functional epidermal molecules 
does not only disturb the structure of the barrier, 
but is also a mediator of immune and allergic pro-
cesses. There is a reciprocal relationship between 
the skin barrier dysfunction and the immune re-
sponse in pathogenesis of AD. Therefore, AD can 
still be considered as a disease of skin barrier im-
pairment and immune disease (49). Mechanisms of 
AD progression into other atopic diseases are not 
quite clear. One of the participants in this process 
is the platelet activating factor (PAF), an endoge-
nous phospholipid inflammatory mediator re-
leased by various types of cells, e.g. alveolar mac-
rophages in allergic and inflammatory conditions 
(50). Release of PAF is associated with increased 
vascular permeability, eosinophilic granulocyte at-
traction, and bronchoconstriction. 
Filaggrin, asthma, and allergic rhinitis 
Data on FLG expression in human digestive tract 
and unified respiratory system are contradictory 
and more often negative (51,52). Moreover, mech-
anisms linking FLG variants with asthma, AR or FA 
are not entirely understandable. However, based 
on some animal models, it is considered that skin 
sensitization, including the Th17 cell subpopula-
tion, facilitated by acquired FLG defects or muta-
tions can indirectly result in local but also systemic 
inflammation in distant organs (53,54). 
Asthma
An estimated 300 million people worldwide suffer 
from asthma (55,56). Asthma is caused by genetic 
predisposition and various external stimuli (e.g. air-
borne allergens), which result in partial or full re-
versible bronchoconstriction. It is often presented 
differently in children and adults; there are different 
phenotypes such as intermittent, persistent, aspirin 
sensitive and severe form. Symptoms mainly in-
volve severe breathing, chest tightness, dyspnoea 
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and cough, especially at night and in the morning 
(55). Asthma is the result of a disturbed interaction 
of the respiratory epithelium, the innate and adap-
tive immune system and the environmental factors. 
In this regard, a large number of genes, particularly 
genes responsible for the Th2 cytokine expression 
in Th2 cells (IL-4, IL-13, IL-5), other T-cell subtypes, 
dendritic cells, eosinophil and neutrophil granulo-
cytes, mast cells, macrophages and IgE were inves-
tigated (57). In the pathogenesis of asthma, the role 
of ADAM33 protein, responsible for bronchial hy-
perresponsiveness, stimulation of smooth muscles 
of the airways, fibroblast proliferation and cytokine 
production has been studied (58). Moreover, the ni-
tric oxide vasodilator system, various growth fac-
tors (e.g. transforming growth factor-beta, granulo-
cyte-macrophage colony-stimulating factor), in-
flammatory lipid mediators such as leukotrienes 
and prostaglandin D2, TSLP which induces key 
changes in dendritic cells and other molecules were 
also investigated (59). Palmer and colleagues first 
described the relationship between the R501X and 
2282del4 variants of FLG genes and asthma in per-
sons with AD (60). Case control, family and popula-
tion studies and/or other FLG mutations, which 
then followed, more clearly indicate the meaning of 
a defective epidermal barrier in pathogenesis, pri-
marily AD, and then other atopic disorders – AR and 
asthma (61,62). Generally, the results of investigat-
ing the association of these conditions with groups 
of subjects of different geographic origin show that 
those patients with FLG mutation have a moderate-
ly higher risk of developing asthma than those with-
out genetic mutation, regardless of AD status (63). 
The risk is significantly higher (3 to 6-fold) in pa-
tients with AD and in carriers of FLG mutation (64). It 
appears that the presence of a particular FLG muta-
tion also has implications for some clinical features 
of asthma such as the severity of the disease, the 
number of acute exacerbations, the degree of air-
way obstruction, and the quantity of asthma con-
trol medications to control the disease (65). 
Allergic rhinitis
Rhinitis is one of the most common chronic condi-
tions in children, but also in adults. It is an inflam-
mation of nasal mucosa, characterized by nasal 
congestion (rhinorrhoea), itching, sneezing, and 
nasal blockage. Causes of rhinitis may be allergies, 
infections, drugs, hormones, various irritants, and 
may also be of idiopathic origin (66). Allergic rhini-
tis is characterized by a Th2 immune response in-
cluding mediators such as IL-4, IL-5, IL-13, whose 
activity results in the formation of IgE and recruit-
ment of eosinophilic and basophilic granulocytes, 
mast cells, which further release different media-
tors, such as histamine and cysteinyl leukotriene, 
as a vasoactive substance (67). About 40% of AR 
patients had asthma, and up to 80% of asthmatic 
patients reported AR (68). These data are not sur-
prising since, besides the anatomical connection, 
the inhaled air is heated, moistened, and filtered in 
the nose to maintain homeostasis of the respirato-
ry system (69). In the literature, therefore, more 
work is devoted to the connection of AR and asth-
ma. Of the mechanisms considered in this connec-
tion, it seems that the most acceptable one is the 
systemic inflammatory response, as cited by 
Chawes (70). The same author found a significant 
association of FLG mutations with AR, but not with 
non-allergic rhinitis. Other authors also report 
about such association (71,72), which supports the 
hypothesis of the primary role of epidermal barrier 
impairment in this disease.
Open questions 
Most of the scientific articles included in this re-
view consider FLG deficiency, in particular caused 
by the FLG mutation, as one of the causes, the key 
risk factor, the AD modifier, and consequently the 
possible causes of atopic march. 
The disruption of the skin barrier function associ-
ated with the lack of FLG in AD is, along with other 
known pathogenic factors, the basis for the aller-
gic sensitization to food allergens and aeroaller-
gens, and the consequent development of asthma 
and AR. The key questions in this context are 1) 
how to predict AD and when to prevent the occur-
rence of AD; 2) whether timely repair of skin barri-
er could prevent progression of AD and thus the 
possible development of asthma and AR; and 3) 
what an appropriate therapeutic strategy should 
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include? To get the correct answers to these ques-
tions, it is necessary to define the best biochemi-
cal, preferably non-invasive markers for the detec-
tion and monitoring of the disease. 
The ideal marker would be the one that would 
make it easier to set up a diagnosis, help assess the 
severity of the disease, identify the phenotypes 
AD, and predict the individual response to the 
therapy. However, the ideal marker does not exist. 
Moreover, laboratory assays currently used in 
practice are mainly focus on monitoring immune 
or inflammatory changes (e.g. total and specific 
IgE, eosinophilic granulocyte counts, cytokine re-
lease assays) and less to control of skin-barrier 
function impairment including FLG deficiency. 
These are for example the determination of TWEL 
and pH of the skin (73,74). 
For the last few decades, scientists have been try-
ing to establish methods for detection of FLG defi-
ciency, its degradation products, or products of 
profilaggrin processing as well as other barrier 
proteins. The analytical samples include skin biop-
sy, animal skin biopsy samples, human skin equiv-
alents and reconstructed skin samples, samples 
collected by tape stripping technique and serum 
(75-80). Non-invasive in vivo methods for investi-
gation of skin components are implemented in 
clinical practice. Among novel methods, Raman 
spectroscopy, an optical biopsy method, offers the 
possibility for real-time characterization of skin 
components, including FLG (81). The concentra-
tion of the NMF ingredients, for example amino 
acids and their derivatives is determined using the 
HPLC method (76). Activities of enzymes involved 
in the processing of profilaggrin into FLG, and FLG 
paraffin-embeded samples are also determined, 
by the use of immunohistochemical staining 
(82,83). In the studies there are also particularly im-
portant methods of genotyping of FLG, as well as 
proteomic analysis of FLG deficiency.
Of the non-invasive markers, it appears that signif-
icant potential for the clinical course of AD and 
therapeutic effect has TSLP expression determina-
tion using tape-stripping approach to sampling 
and mass spectrometry as well as determination 
of serum TSLP concentration by enzyme-linked 
immunosorbent assay (ELISA) (84,85). Also, thymus 
and activation-regulated chemokine (TARC), high-
affinity ligand for CC-chemokine receptor 4 (CCR4) 
in serum or plasma of patients has been proposed 
as a marker of disease activity (86,87). 
A significant number of biomarkers include direct 
or indirect evaluation of FLG deficiency. However, 
taking into account the multifactorial nature of 
AD, it is necessary to define more clearly the most 
reliable biomarker for a single phenotype AD (12). 
Accordingly, it will also be possible to apply appro-
priate therapy with the aim of repairing the skin 
barrier.
In addition to the appropriate preventive meas-
ures, effective therapeutic approach to maintain 
adequate skin barrier function and inflammatory 
control are also needed. Within primary non-phar-
macological prevention, some authors advise 
avoiding various types of allergens, while some 
promote tolerance. Early sensitization in the first 
year of life, especially to food allergens, e.g. pea-
nuts and milk, increases the risk for asthma to the 
third year of life of a children even 7-fold (88). Oth-
er authors state that sensitization to food allergens 
can develop before food is consumed, and that it 
occurs through inflammation of the skin (allergens 
can be found in home dust and creams and oils 
used for the treatment of new-born babies) (89). It 
is therefore considered that early oral consump-
tion of such food can lead to tolerance, and that 
transcutaneous exposure to food allergens can 
lead to food sensitization. Based on the described 
causal link between early sensitization through 
damaged skin barrier and later development of at-
opic diseases such as asthma and AR, Johanson 
and Hershey promote immune tolerance as a 
“therapeutic” strategy or early introduction of “al-
lergic” food (90). It has been described that the 
permeability of new-born skin is increased due to 
the insufficient presence of ceramide, which is as-
sociated with increased risk of later development 
of AD (91). A review by Lowe et al. focused on skin 
as a goal for the prevention of atopic march in-
cludes the concept of preventive skin treatment 
with emollients from the first weeks of life to 6 or 8 
months of age, i.e. prevention before the onset of 
symptoms of AD (92). Few well-designed larger tri-
Biochem Med (Zagreb) 2019;29(2):020501   https://doi.org/10.11613/BM.2019.020501 
10
Čepelak I. et al. Filaggrin and atopic march
als are currently underway to demonstrate the 
long-term effects of moisturizing on the incidence 
of AD and on the incidence of FA and allergic air-
ways disease. The authors discuss the advantages 
and disadvantages of such a strategy, as well as 
the choice of emollients, and their safety and ac-
ceptability (92). 
As a part of the primary therapeutic prevention of 
further AD development, as well as prevention of 
progression in asthma and AR, methods for com-
pensation of reduced FLG level or its degradation 
products (NMF) are also developed.
According to Irvine, the group of candidates for 
FLG replacement therapy would include patients 
with FLG mutations, patients with variation in FLG 
repeat numbers, intra-genetic copy number varia-
tion, patients with secondary reduced FLG (ac-
quired deficiency), severe and persistent type of 
AD that have allergic sensitization and in the fu-
ture could develop asthma, and patients with 
genodermatoses (93). Currently, about 80 clinical 
trials focused on topical AD treatment are ongo-
ing, including drugs that would have the ultimate 
effect on FLG increase (94). Animal and human in-
vestigations of drugs focused on mutant alleles, 
drugs increasing FLG expression by promotion of a 
healthy allele, direct FLG substitution drugs, hence 
recombinant FLG are currently underway (95). Oth-
er therapeutic measures are the renewal of extra-
cellular skin lipid profiles (various emollients with a 
mixture of ceramides, cholesterol, and fatty acids), 
regeneration of pH, and skin hydration. As im-
mune dysregulation remains the key problem in 
AD and shares pathophysiological features with 
other atopic disorders, it is very important to con-
trol inflammation. Various biological drugs such as 
dupilumab (monoclonal antibody directed against 
the IL-4 receptor α subunit that blocks signaling of 
both IL-4 and IL-13), nemolizumab (target IL-13), 
ustekinumab and lebrikizumab (targeting IL-31) 
are in research (31,96,97). However, further investi-
gations should be used to determine the timing of 
the initiation of preventive measures, the effec-
tiveness of various forms of therapy, safety, and 
the mode of administration/dosage and the dura-
tion of the effect. 
Conclusion
It is indisputable that the interactions between im-
paired epidermal barrier and dysregulation of the 
innate and adaptive immune system, in associa-
tion with environmental risk factors, are involved 
in pathogenesis of AD. Atopic dermatitis is the 
most commonly occurring disease in an early life, 
which is associated with increased risk of asthma 
and AR. The scientific literature is dominated by 
works that AD of hereditary or other origin are 
considered as an initiating event in the atopic 
march and the lack of FLG as a key component of 
the epidermal differentiation complex, as one of 
the first participants in pathogenesis of AD. In this 
context, if the skin barrier function is impaired, or 
if it is not repaired in the case of a pathogenic pro-
cess already exists, it will be possible to provide a 
continuous allergen entrance, and the immune 
system will continuously produce antibodies. It is 
therefore expected that, along with various pre-
ventive measures recommended for maintaining 
the barrier function, therapeutic-oriented barrier 
restoration in this context of FLG replacement and 
AD prevention will minimize the risk of allergic im-
munization as well as the development of asthma 
and AR. To monitor the effect of such therapy and 
the therapy that is in use, it is also necessary to 
find suitable laboratory markers. The complete 
pathogenesis of AD and the pathway to explain at-
opic march, despite numerous new findings, in-
cluding the significance of FLG deficiency, are still 
not quite clear due to their complexity and are in 
the focus of numerous researchers. 
Accordingly, researchers should continue to work 
on the identification of molecular basis and envi-
ronmental triggers of AD, on the association of the 
immune system with FLG deficiency, but also with 
other proteins of the epidermal differentiation 
complex. That will help to establish appropriate 
prevention and therapeutic algorithms to prevent 
or at least slow the atopic march.
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